A case of psoriasiform eruption triggered by tumor necrosis factor-alpha antagonist therapy

Jin Choi Yoon, Suk Kim Dae, Mo Park Jin, Ho Oh Sang, Yoon Kee Park, Hee Lee Ju

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Tumor necrosis factor-alpha antagonists include monoclonal antibodies, infliximab, adalimumab, etanercept and golimumab. Clinical trials of these agents have shown that they are remarkably effective for psoriasis, but cutaneous adverse reactions of these agents including paradoxical aggravation of psoriasiform eruption have been also reported. We present a case of psoriasiform eruption triggered by golimumab therapy in a patient with rheumatoid arthritis. A 53-year-old woman presented with a skin lesion on the sole. She had been treated by golimumab every 4 weeks for rheumatoid arthritis from September 2006. 16 weeks after the treatment, she developed a erythematous and scaly patch on the sole. She had a history of palmoplantar pustulosis, but the skin lesions had not appeared for a long time, recurring when she started golimumab treatment. The skin lesion improved with topical steroid treatment, but as golimumab was re-administrated, the skin lesion exacerbated.

Original languageEnglish
Pages (from-to)721-723
Number of pages3
JournalKorean Journal of Dermatology
Volume46
Issue number5
Publication statusPublished - 2008 May 1

Fingerprint

Tumor Necrosis Factor-alpha
Skin
Rheumatoid Arthritis
Therapeutics
Psoriasis
Steroids
Monoclonal Antibodies
golimumab
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Yoon, Jin Choi ; Dae, Suk Kim ; Jin, Mo Park ; Sang, Ho Oh ; Park, Yoon Kee ; Ju, Hee Lee. / A case of psoriasiform eruption triggered by tumor necrosis factor-alpha antagonist therapy. In: Korean Journal of Dermatology. 2008 ; Vol. 46, No. 5. pp. 721-723.
@article{019a40f5ac2846f8b5608176c13c9271,
title = "A case of psoriasiform eruption triggered by tumor necrosis factor-alpha antagonist therapy",
abstract = "Tumor necrosis factor-alpha antagonists include monoclonal antibodies, infliximab, adalimumab, etanercept and golimumab. Clinical trials of these agents have shown that they are remarkably effective for psoriasis, but cutaneous adverse reactions of these agents including paradoxical aggravation of psoriasiform eruption have been also reported. We present a case of psoriasiform eruption triggered by golimumab therapy in a patient with rheumatoid arthritis. A 53-year-old woman presented with a skin lesion on the sole. She had been treated by golimumab every 4 weeks for rheumatoid arthritis from September 2006. 16 weeks after the treatment, she developed a erythematous and scaly patch on the sole. She had a history of palmoplantar pustulosis, but the skin lesions had not appeared for a long time, recurring when she started golimumab treatment. The skin lesion improved with topical steroid treatment, but as golimumab was re-administrated, the skin lesion exacerbated.",
author = "Yoon, {Jin Choi} and Dae, {Suk Kim} and Jin, {Mo Park} and Sang, {Ho Oh} and Park, {Yoon Kee} and Ju, {Hee Lee}",
year = "2008",
month = "5",
day = "1",
language = "English",
volume = "46",
pages = "721--723",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "5",

}

A case of psoriasiform eruption triggered by tumor necrosis factor-alpha antagonist therapy. / Yoon, Jin Choi; Dae, Suk Kim; Jin, Mo Park; Sang, Ho Oh; Park, Yoon Kee; Ju, Hee Lee.

In: Korean Journal of Dermatology, Vol. 46, No. 5, 01.05.2008, p. 721-723.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A case of psoriasiform eruption triggered by tumor necrosis factor-alpha antagonist therapy

AU - Yoon, Jin Choi

AU - Dae, Suk Kim

AU - Jin, Mo Park

AU - Sang, Ho Oh

AU - Park, Yoon Kee

AU - Ju, Hee Lee

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Tumor necrosis factor-alpha antagonists include monoclonal antibodies, infliximab, adalimumab, etanercept and golimumab. Clinical trials of these agents have shown that they are remarkably effective for psoriasis, but cutaneous adverse reactions of these agents including paradoxical aggravation of psoriasiform eruption have been also reported. We present a case of psoriasiform eruption triggered by golimumab therapy in a patient with rheumatoid arthritis. A 53-year-old woman presented with a skin lesion on the sole. She had been treated by golimumab every 4 weeks for rheumatoid arthritis from September 2006. 16 weeks after the treatment, she developed a erythematous and scaly patch on the sole. She had a history of palmoplantar pustulosis, but the skin lesions had not appeared for a long time, recurring when she started golimumab treatment. The skin lesion improved with topical steroid treatment, but as golimumab was re-administrated, the skin lesion exacerbated.

AB - Tumor necrosis factor-alpha antagonists include monoclonal antibodies, infliximab, adalimumab, etanercept and golimumab. Clinical trials of these agents have shown that they are remarkably effective for psoriasis, but cutaneous adverse reactions of these agents including paradoxical aggravation of psoriasiform eruption have been also reported. We present a case of psoriasiform eruption triggered by golimumab therapy in a patient with rheumatoid arthritis. A 53-year-old woman presented with a skin lesion on the sole. She had been treated by golimumab every 4 weeks for rheumatoid arthritis from September 2006. 16 weeks after the treatment, she developed a erythematous and scaly patch on the sole. She had a history of palmoplantar pustulosis, but the skin lesions had not appeared for a long time, recurring when she started golimumab treatment. The skin lesion improved with topical steroid treatment, but as golimumab was re-administrated, the skin lesion exacerbated.

UR - http://www.scopus.com/inward/record.url?scp=50249181130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249181130&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:50249181130

VL - 46

SP - 721

EP - 723

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 5

ER -